Objectif The increasing occurrence of multidrug-resistant Mycobacterium tuberculosis strains makes tuberculosis (TB) a key priority for infectious disease research. Inflammation and autophagy are two fundamental processes critical to TB pathogenesis. Accumulating evidence shows that TB disease is worsened by deregulation of the inflammatory response. On the other hand, autophagy has recently emerged as a crucial host defence mechanism. Autophagy counteracts the ability of mycobacteria to survive inside host cells and targets them for degradation. Autophagy is also thought to control the inflammatory response. However, the interaction between inflammation and autophagy in host defence against TB remains unclear. The aim of my proposal is to use the well-established zebrafish model of TB to gain insight into this key question. Recently, the host laboratory discovered that the DNA damage-regulated autophagy modulator (DRAM1) protects against TB in the zebrafish model. They also implicated this important autophagy regulator in inflammation, as it strongly affects expression of interleukin-1beta (IL1B). I have specific expertise in studying IL1B-mediated inflammation in zebrafish. Thus the proposed project will be a great synergy between me and the host laboratory, which is leading in zebrafish infectious disease research. I will determine how modulation of autophagy or manipulation of IL1B levels reciprocally influence each other during TB disease. The zebrafish model provides excellent tools to visualize these processes in vivo. Furthermore, I will take advantage of the host’s expertise in RNA sequencing and proteomics to study genome-wide effects of autophagy modulation on the inflammatory response. A secondment will allow me to compare results in the TB model with a damage-induced inflammation model. The project will provide new insights into regulatory pathways that could potentially be intervened in treatment of TB or other inflammatory diseases with common characteristics. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinflammatory diseasesmedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesclinical medicinepneumologytuberculosismedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Thème(s) MSCA-IF-2014-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Appel à propositions H2020-MSCA-IF-2014 Voir d’autres projets de cet appel Régime de financement MSCA-IF-EF-ST - Standard EF Coordinateur UNIVERSITEIT LEIDEN Contribution nette de l'UE € 177 598,80 Adresse RAPENBURG 70 2311 EZ Leiden Pays-Bas Voir sur la carte Région West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 177 598,80